Want to see IN:PPLPHARMA full AI Analyst Report?
PPLPHARMA Stock Chart & Stats
₹192.65
-₹4.80(-1.92%)
At close: 4:00 PM EST
₹192.65
-₹4.80(-1.92%)
Day’s Range― - ―
52-Week Range₹132.50 - ₹220.40
Previous CloseN/A
Volume1.66M
Average Volume (3M)264.14K
Market Cap
₹284.31B
Enterprise Value₹223.95K
Total Cash (Recent Filing)₹13.55B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 11, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend Yield0.07%
Share Statistics
EPS (TTM)-2.37
Shares Outstanding1,331,348,100
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.22
Price to Sales (P/S)2.04
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.36
Revenue Forecast (FY)₹101.40B
Bulls Say, Bears Say
Bulls Say
Revenue Scale-upSustained top-line growth over multiple years indicates expanding commercial traction across CDMO, hospital generics and OTC channels. Durable revenue scale supports higher capacity utilization, better fixed-cost absorption, and provides a foundation for reinvestment in tech, capacity and global customer relationships.
Improving Cash GenerationMarked improvement in operating cash flow and a return to positive free cash flow demonstrate stronger cash conversion and working-capital management. This durable improvement enhances self-funding for capex, supports debt servicing, and increases optionality for strategic investments or contract bids over the medium term.
Diversified Pharma Business ModelA multi-segment model spanning CDMO, specialty generics and consumer health reduces reliance on any single revenue stream. Structural diversification combines sticky CDMO contracts with repeat hospital orders and steady OTC sales, improving resilience to product-specific or customer-specific shocks over a 2–6 month to multi-year horizon.
Bears Say
Volatile Profitability And Loss YearsRecurring swings to net losses undermine earnings quality and predictability. Volatile profits complicate capital allocation, raise credit risk during downturns, and can erode retained equity. If losses persist, they may force cost cuts or asset sales that impair long-term growth initiatives.
Rising Debt From Earlier YearsHigher leverage increases interest and refinancing risk, reducing financial flexibility during earnings volatility. Elevated debt limits capacity for expansion or acquisitions financed internally, may tighten covenant headroom, and raises the sensitivity of returns to operational setbacks over the medium term.
Inconsistent Returns On CapitalIrregular ROE signals the company struggles to reliably convert invested capital into profits. This makes forecasting and long-term capital planning harder, can reduce investor confidence in management's allocation decisions, and may limit ability to fund growth from internal returns.
Piramal Pharma Limited News
PPLPHARMA FAQ
What was Piramal Pharma Limited’s price range in the past 12 months?
Piramal Pharma Limited lowest stock price was ₹132.50 and its highest was ₹220.40 in the past 12 months.
What is Piramal Pharma Limited’s market cap?
Piramal Pharma Limited’s market cap is ₹284.31B.
When is Piramal Pharma Limited’s upcoming earnings report date?
Piramal Pharma Limited’s upcoming earnings report date is Nov 11, 2026 which is in 78 days.
How were Piramal Pharma Limited’s earnings last quarter?
Piramal Pharma Limited released its earnings results on Jul 29, 2026. The company reported -₹0.5 earnings per share for the quarter, beating the consensus estimate of -₹0.66 by ₹0.16.
Is Piramal Pharma Limited overvalued?
According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued.
Does Piramal Pharma Limited pay dividends?
Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.07%. See more information on Piramal Pharma Limited dividends here
What is Piramal Pharma Limited’s EPS estimate?
Piramal Pharma Limited’s EPS estimate is -0.01.
How many shares outstanding does Piramal Pharma Limited have?
Piramal Pharma Limited has 1,331,348,100 shares outstanding.
What happened to Piramal Pharma Limited’s price movement after its last earnings report?
Piramal Pharma Limited reported an EPS of -₹0.5 in its last earnings report, beating expectations of -₹0.66. Following the earnings report the stock price went up 1.215%.
Which hedge fund is a major shareholder of Piramal Pharma Limited?
Currently, no hedge funds are holding shares in IN:PPLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Jubilant Ingrevia Ltd.
―
Syngene International Ltd.
―